Ardelyx (ARDX) Q4 2025 earnings summary

Executive summary

• Achieved all 2025 strategic priorities, including strong commercial execution, pipeline expansion, and robust financial performance, with IBSRELA driving growth and positive cash flow in the second half of 2025.

• IBSRELA revenue grew 73% year-over-year to $274.2 million, becoming a key growth engine, while XPHOZAH contributed $103.6 million despite Medicare reimbursement changes.

• Launched two new pipeline programs, including a Phase 3 trial for tenapanor in CIC and preclinical work on next-generation NHE3 inhibitor RDX10531.

• New formulation patent for IBSRELA and XPHOZAH extends protection to 2042.

• Ended 2025 with a strong financial position and $264.7 million in cash, cash equivalents, and short-term investments.

Financial highlights

• Total 2025 revenue grew 22% year-over-year to $407.3 million, primarily due to IBSRELA growth.

• IBSRELA revenue reached $274.2 million, up 73% from 2024; XPHOZAH revenue was $103.6 million, down 36% due to loss of Medicare Part D reimbursement.

• Other revenues, including product supply, licensing, and non-cash royalty, totaled $29.5 million, more than doubling year-over-year.

• Net loss for 2025 was $61.6 million ($0.26/share), compared to $39.1 million ($0.17/share) in 2024.

• R&D expenses rose to $71.5 million (from $52.3 million), and SG&A expenses increased to $337.2 million (from $258.7 million) year-over-year.

Outlook and guidance

• 2026 product revenue guidance is $520–550 million, with IBSRELA expected to reach $410–430 million (at least 50% growth) and XPHOZAH projected at $110–120 million.

• IBSRELA projected to reach $1 billion in annual revenue by 2029, with a 38% CAGR.

• XPHOZAH expected to reach $750 million before patent expiration in 2034.

• 2026 operating expenses expected to increase by ~25% to $520 million, driven by R&D and SG&A investments.

• Enrollment for the CIC Phase 3 trial expected to complete by end of 2026, with topline results in H2 2027.